Becton Dickinson & Co. closed 28.21% short of its 52-week high of $251.99, which the company reached on February 3rd.

In its second quarter 2025 investor letter, Oakmark Global Fund highlighted stocks such as Becton, Becton, Dickinson and ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

Key Takeaways Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider ...

BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Milford-based biotech company Waters Corp. will merge with Becton, Dickinson and Co.’s biosciences an diagnostic solutions ...